Skip to main content
Anthem Biosciences Limited logo

Anthem Biosciences Limited — Investor Relations & Filings

Ticker · ANTHEM ISIN · INE0CZ201020 LEI · 335800FNA941U9NMD221 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 84 across all filing types
Latest filing 2026-05-19 Earnings Release
Country IN India
Listing BSE.NS ANTHEM

About Anthem Biosciences Limited

https://anthembio.com/

Anthem Biosciences Limited is a comprehensive Contract Research and Manufacturing Services (CRAMS) organization providing integrated solutions across the drug discovery and development lifecycle. The company offers services including medicinal chemistry, process research, analytical validation, and large-scale commercial manufacturing. Its technical expertise spans synthetic organic chemistry, fermentation technology, molecular biology, and cell biology, enabling the production of both small molecules and biologics. Anthem serves global clients in the pharmaceutical, biopharmaceutical, and specialty chemical sectors. The organization features state-of-the-art research facilities and cGMP-compliant manufacturing units, facilitating a seamless transition from initial concept to market-ready products. Its commitment to intellectual property protection and rigorous quality management systems underpins its collaborative partnerships.

Recent filings

Filing Released Lang Actions
The Board in its meeting held on May 19, 2026 has approved the allotment of 14,81,250 equity shares to eligible employees upon exercise of options vested under Anthem Employee Stock Option Plan 2024
Earnings Release Classification · 85% confidence The document is a formal stock exchange filing under SEBI Listing Regulations announcing the outcomes of the Board Meeting held on May 19, 2026, which primarily includes the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 along with the Independent Auditor’s Report, dividend recommendation, AGM date, share allotments, and director appointments. It is the initial public disclosure of full period financial results rather than the full Annual Report. This aligns with the “Earnings Release (ER)” category, which covers initial announcements of periodical financial results. FY 2026
2026-05-19 English
Press Release
Earnings Release Classification · 90% confidence The document is a press release filed under SEBI Regulation 30 to BSE and NSE announcing the audited consolidated financial results for Q4 FY26 and full year FY26 with key highlights (Revenue, EBITDA, PAT, margins) in summary table form, along with earnings call details. It contains summary financial results rather than full statutory financial statements. This fits the definition of an Earnings Release (initial announcement of quarterly/period financial results). FY 2026
2026-05-19 English
Key Performance Indicators for the financial year 2025-26
Audit Report / Information Classification · 85% confidence The document is a certificate issued by external auditors (K.P. Rao & Co.) verifying and attesting to the accuracy of the company’s Key Performance Indicators under SEBI regulations. It is not an earnings release, management discussion, proxy statement, or full financial report; rather it is a standalone audit/assurance certificate. Under our taxonomy, this falls under Audit Report / Information (Code: AR). FY 2026
2026-05-19 English
General Updates
Regulatory Filings Classification · 87% confidence The document is a standalone certificate by the company’s chartered accountants verifying Key Performance Indicators (KPIs) under SEBI regulations. It does not contain full audited financial statements like an Annual Report (10-K) or Interim Report (IR), nor is it a press release of results. Instead, it is an attestation/certification letter for KPI data, which per the Certification Rule should be classified as a general regulatory filing. Therefore, it falls under Regulatory Filings (RNS).
2026-05-19 English
Reappoint of Mr. Ravindra Chandrappa, Whole Time Director, who retires by rotation and being eligible offers himself for re-appointment and Continuation of appointment of Mr. Ravikant ....
Audit Report / Information Classification · 90% confidence The document is the formal outcome of the Board meeting under SEBI LODR Regulations, featuring audited standalone and consolidated financial results for the year ended March 31, 2026, accompanied by the Independent Auditor’s Report under Regulation 33. It is not a full Annual Report (10-K), nor merely an earnings highlights release (ER), nor a brief publication notice (RPA). It primarily comprises the auditor’s opinion and statutory audit details, fitting the “Audit Report / Information” category. FY 2026
2026-05-19 English
Record date for final dividend
Regulatory Filings Classification · 85% confidence The document is an SEBI LODR ‘‘Outcome of Board Meeting’’ notice filed with BSE/NSE, summarizing and approving the audited standalone and consolidated financial results, enclosing the auditor’s report, dividend recommendation, AGM date, ESOP allotment, auditor re-appointment, and director re-appointments. It is not the full Annual Report (10-K) nor simply a brief earnings release (ER) or interim report (IR), and although it includes an independent auditor’s report, it serves as a broader regulatory disclosure under Listing Regulations. Accordingly, it best fits the catch-all “Regulatory Filings” category (RNS).
2026-05-19 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.